about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
Company profile
Ticker
VCEL
Exchange
Website
CEO
Dominick Colangelo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AASTROM BIOSCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Vericel Denmark ApS • Vericel Security Corporation ...
IRS number
943096597
VCEL stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
21 Mar 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
29 Feb 24
8-K
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
9 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
8 Nov 23
8-K
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
20 Sep 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
Transcripts
VCEL
Earnings call transcript
2023 Q4
29 Feb 24
VCEL
Earnings call transcript
2023 Q3
8 Nov 23
VCEL
Earnings call transcript
2023 Q2
2 Aug 23
VCEL
Earnings call transcript
2023 Q1
10 May 23
VCEL
Earnings call transcript
2022 Q4
23 Feb 23
VCEL
Earnings call transcript
2022 Q3
9 Nov 22
VCEL
Earnings call transcript
2022 Q2
3 Aug 22
VCEL
Earnings call transcript
2022 Q1
4 May 22
VCEL
Earnings call transcript
2021 Q4
24 Feb 22
VCEL
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
17 Apr 24
4
Alan L Rubino
11 Apr 24
4
ROBERT L MD ZERBE
29 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Dominick Colangelo
15 Mar 24
4/A
Sean C. Flynn
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Michael Halpin
13 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.56 mm | 83.56 mm | 83.56 mm | 83.56 mm | 83.56 mm | 83.56 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.69 mm | 1.05 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 11.15 mm | 6.93 mm | n/a | n/a |
Cash remaining | n/a | n/a | 72.41 mm | 76.63 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 43.0 | 73.1 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 209 |
Opened positions | 28 |
Closed positions | 18 |
Increased positions | 76 |
Reduced positions | 74 |
13F shares | Current |
---|---|
Total value | 1.66 tn |
Total shares | 51.72 mm |
Total puts | 12.50 k |
Total calls | 72.00 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.48 mm | $250.64 bn |
Brown Capital Management | 6.88 mm | $230.60 bn |
Vanguard | 3.33 mm | $111.47 bn |
RTW Investments | 3.29 mm | $110.34 bn |
STT State Street | 2.69 mm | $90.29 bn |
Conestoga Capital Advisors | 2.23 mm | $74.77 bn |
GW&K Investment Management | 1.37 mm | $45.96 bn |
MS Morgan Stanley | 1.36 mm | $45.47 bn |
Loomis Sayles & Co L P | 1.18 mm | $39.52 bn |
MCQEF Macquarie | 1.17 mm | $39.36 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Rubino Alan L | Common Stock | Option exercise | Acquire M | No | No | 4.12 | 3,000 | 12.36 k | 20,594 |
9 Apr 24 | Rubino Alan L | Stock Option Common Stock | Option exercise | Acquire M | No | No | 4.12 | 3,000 | 12.36 k | 0 |
27 Mar 24 | Zerbe Robert L MD | Common Stock | Sell | Dispose S | No | Yes | 51.57 | 3,278 | 169.05 k | 23,395 |
27 Mar 24 | Zerbe Robert L MD | Common Stock | Option exercise | Acquire M | No | No | 3.74 | 3,278 | 12.26 k | 26,673 |
27 Mar 24 | Zerbe Robert L MD | Stock Option Common Stock | Option exercise | Acquire M | No | No | 3.74 | 3,278 | 12.26 k | 0 |
14 Mar 24 | Colangelo Dominick | Common Stock | Sell | Dispose S | No | Yes | 44.02 | 17,500 | 770.35 k | 194,870 |
14 Mar 24 | Colangelo Dominick | Common Stock | Option exercise | Acquire M | No | No | 3.02 | 17,500 | 52.85 k | 212,370 |
14 Mar 24 | Colangelo Dominick | Stock Option Common Stock | Option exercise | Acquire M | No | No | 3.02 | 17,500 | 52.85 k | 280,000 |
13 Mar 24 | Colangelo Dominick | Common Stock | Sell | Dispose S | No | Yes | 44.67 | 17,500 | 781.73 k | 194,870 |
13 Mar 24 | Colangelo Dominick | Common Stock | Option exercise | Acquire M | No | No | 3.02 | 17,500 | 52.85 k | 212,370 |
News
Analyst Scoreboard: 5 Ratings For Vericel
26 Mar 24
Truist Securities Reiterates Buy on Vericel, Maintains $54 Price Target
26 Mar 24
A Closer Look at 4 Analyst Recommendations For Vericel
1 Mar 24
Truist Securities Maintains Buy on Vericel, Raises Price Target to $54
1 Mar 24
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $53
1 Mar 24